Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Baetz T, Chen BE, Couban S, Tom Kouroukis C, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Baetz T, et al. Among authors: federico m. Leuk Lymphoma. 2017 Jan;58(1):64-69. doi: 10.1080/10428194.2016.1187274. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27266754
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M, Morabito F, Merli F, Molica S, Cavanna L, Sacchi S, Broglia C, Angrilli F, Ilariucci F, Stelitano C, Luisi D, Bertè R, Luminari S, Federico M, Brugiatelli M; GISL. Lombardo M, et al. Among authors: federico m. Leuk Lymphoma. 2002 Sep;43(9):1795-801. doi: 10.1080/1042819021000006457. Leuk Lymphoma. 2002. PMID: 12685834
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, Moretti L, Colombat P, Luminari S, Fabbiano F, Di Renzo N, Goldstone A, Carella AM; EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. Federico M, et al. J Clin Oncol. 2003 Jun 15;21(12):2320-5. doi: 10.1200/JCO.2003.11.103. J Clin Oncol. 2003. PMID: 12805333 Clinical Trial.
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, Merli F, Alterini R, Petrucci MT, Tani M, Liberati AM, Vitolo U, Pavone V, Cuneo A, Chisesib T, Brugiatelli M; Intergruppo Italiano Linfomi. Rigacci L, et al. Among authors: federico m. Leuk Lymphoma. 2003 Nov;44(11):1911-7. doi: 10.1080/1042819031000123564. Leuk Lymphoma. 2003. PMID: 14738142
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Di Renzo N, Brugiatelli M, Montanini A, Vigliotti ML, Cervetti G, Liberati AM, Luminari S, Spedini P, Giglio G, Federico M. Di Renzo N, et al. Among authors: federico m. Leuk Lymphoma. 2006 Mar;47(3):473-9. doi: 10.1080/10428190500312295. Leuk Lymphoma. 2006. PMID: 16396771 Clinical Trial.
The role of anthracyclines in follicular lymphomas.
Luminari S, Federico M. Luminari S, et al. Among authors: federico m. Leuk Lymphoma. 2006 Nov;47(11):2267-8. doi: 10.1080/10428190600822086. Leuk Lymphoma. 2006. PMID: 17107893 No abstract available.
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Mannina D, Luminari S, Dondi A, Polimeno G, Baldini L, Stelitano C, Merli F, Dell'Olio M, Gobbi PG, Giglio G, Barbolini E, Brugiatelli M, Federico M. Mannina D, et al. Among authors: federico m. Leuk Lymphoma. 2010 Mar;51(3):422-9. doi: 10.3109/10428190903518352. Leuk Lymphoma. 2010. PMID: 20038237
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study.
Mian M, Gaidano G, Conconi A, Tsang R, Gospodarowicz MK, Rambaldi A, Rossi A, Oldani E, Federico M, Luminari S, Bellei M, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Lopez-Guillermo A, Busetto M, Cavalli F, Zucca E, Cortelazzo S. Mian M, et al. Among authors: federico m. Leuk Lymphoma. 2011 May;52(5):823-32. doi: 10.3109/10428194.2011.555888. Epub 2011 Feb 21. Leuk Lymphoma. 2011. PMID: 21338283 Clinical Trial.
Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy.
Luminari S, Cesaretti M, Tomasello C, Guida A, Bagni B, Merli F, Postiglione R, Mangone L, Versari A, Re F, De Lisi V, Ruffini L, Ferretti S, Cuneo A, Federico M. Luminari S, et al. Among authors: federico m. Leuk Lymphoma. 2011 Sep;52(9):1689-96. doi: 10.3109/10428194.2011.580475. Epub 2011 Jun 12. Leuk Lymphoma. 2011. PMID: 21663500
Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.
Gobbi PG, Valentino F, Bassi E, Coriani C, Merli F, Bonfante V, Marchianò A, Gallamini A, Bolis S, Stelitano C, Levis A, Federico M, Angrilli F, Di Giulio G, Corazza GR. Gobbi PG, et al. Among authors: federico m. Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):396-402. doi: 10.1016/j.clml.2011.04.008. Epub 2011 Jun 12. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21729691
761 results